Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS +1.82%19 EV-to-FCF is -53.34 as of Jul. 27, 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 568 Drug Manufacturers companies, Curis Lifesciences ranks worse than 176056.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Curis Lifesciences's Enterprise Value is ₹989.7 Mil.
Curis Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-18.6 Mil. Therefore, Curis Lifesciences's EV-to-FCF for today is -53.34.
The historical rank and industry rank for Curis Lifesciences's EV-to-FCF or its related term are showing as below:
NSE:CURIS'
s EV-to-FCF Range Over the Past 10 Years
Min: -69.68 Med: -55.96 Max: -48.07
Current: -53.34
During the past 4 years, the highest EV-to-FCF of Curis Lifesciences was -48.07. The lowest was -69.68. And the median was -55.96.
NSE:CURIS's EV-to-FCF is ranked worse than 100% of 568
companies
in the Drug Manufacturers industry
Industry Median: 20.585
vs NSE:CURIS: -53.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Curis Lifesciences's PE Ratio (TTM) for today is calculated as:
Curis Lifesciences's share price for today is ₹112.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curis Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹37.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Curis Lifesciences EV-to-FCF Related Terms
Curis Lifesciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences EV-to-FCF Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EV-to-FCF
0.00
0.00
0.00
0.00
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
EV-to-FCF
0.00
0.00
0.00
0.00
NSE:CURIS vs ZTS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's EV-to-FCF falls into.
Curis Lifesciences's current Enterprise Value is ₹989.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curis Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-18.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a EV-to-FCF of -53.34 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Curis Lifesciences and its competitors. According to the industry distribution chart, Curis Lifesciences ranks #999999 out of 568 companies in the Drug Manufacturers industry.
Is Curis Lifesciences' EV-to-FCF too high?
Curis Lifesciences' current EV-to-FCF is -53.34. Based on the distribution chart, Curis Lifesciences ranks #999999 out of 568 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #999999 out of 568 companies for EV-to-FCF. This places Curis Lifesciences in the lower half of its industry. The industry median EV-to-FCF is 20.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.59, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current EV-to-FCF is -53.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current EV-to-FCF of -53.34. The current EV-to-FCF is -53.34. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current EV-to-FCF is -53.34 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
